ZTSBy Calypso Research7 min read

Zoetis Inc. (ZTS) Q4 2025 Earnings Analysis

Zoetis Faces Paws and Claws with $2.4B in Revenue

Key Takeaways

Zoetis Inc. (ZTS) reported Q4 2025 earnings with revenue of $2.4B, representing a +3.0% year-over-year change. The stock moved -2.4% on earnings day.

The bull case: Bulls argue that Zoetis’ diversified portfolio, entrenched leadership in parasiticides and dermatology, and a deep late‑stage pipeline set up a temporary 2026 digestion year before growth re‑accelerates toward its historical high‑single‑digit trajectory in 2027 and beyond.

The bear case: Bears contend that rising competition in key franchises, sustained OA pain headwinds, macro‑driven pressure on U.S. companion animal demand, and reduced reliance on price hikes signal a structurally slower, lower‑margin growth profile than investors have historically paid a premium for.

Financial Highlights

  • Revenue: $2.4B (+3.0% YoY)
  • Gross Profit: $1.6B (68.9% margin, +0.9% YoY)
  • Operating Income: $826M (34.6% margin, +1.6% YoY)
  • Net Income: $603M
  • TTM Revenue: $9.5B

Stock Performance

  • Earnings Day Move: -2.4%
  • Year-to-Date: -0.1%
  • 1-Year Return: -23.9%
  • vs. S&P 500 (since earnings): +2.6%
  • vs. Nasdaq (since earnings): +5.3%

View live ZTS data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Zoetis Inc.'s Q4 2025 earnings call:

2026 Top‑Line Guidance (3–5%) vs. Accounting Noise and Macro Headwinds

Sentiment: Mixed

"Our 3% to 5% operational growth…is our expectations for 2026 on the same basis that we have always reported, and, certainly, that factors the baseline, which is 2025, and the performance throughout the year inclusive of the fourth quarter." — Wetteny Joseph
"Put into context here, the amount we are talking about for 2025 is effectively 30 basis points to 40 basis points of the total company…This is not a significant amount that would swing the range of growth that we are projecting for 2026 in any material way." — Wetteny Joseph

Competitive Intensity in Dermatology and Parasiticides (Trio, Key Derm) and Impact on Growth

Sentiment: Positive

"We do take various scenarios into consideration, including when we expect competition to launch and the level of aggressive promotions that they will do…including…another JAK competitor launching potentially in the U.S., as well as in terms of IL‑31 in that sense as well." — Wetteny Joseph
"Trio itself had a great year…The U.S., similar to derm, due to the macro conditions that we have talked about, saw lower growth net, closer to 1% on the quarter…Trio is the clear leader in parasiticides in the U.S. and the clear leader in terms of triple combinations." — Wetteny Joseph

U.S. Companion Animal Demand, Vet Pricing, and Pet Owner Elasticity

Sentiment: Positive

"We did continue to see some deceleration…in traffic in both therapeutic and wellness…I think there was really just pricing at the vet clinic taken a lot over the last three years, and I think the view from the pet owners is it was a little much." — Kristin Peck
"As we look at the year, as we move forward through the year, we do see an improvement overall in the pet owner macro situation, and that is certainly what we are expecting." — Kristin Peck

Librela / OA Pain Franchise Headwinds vs. Long‑Term Opportunity (Lanivia, Portela)

Sentiment: Mixed

"Our U.S. Companion Animal decline was driven primarily by headwinds from our OA mAb franchises, which declined 25% in the quarter…We are continuing to execute on our multipronged strategy and remain confident that our OA pain portfolio will return to growth." — Wetteny Joseph
"We are very excited right now to be launching in the first half for Lanivia in the EU and Canada…And we do expect approval of Lanivia in the U.S. in 2027." — Kristin Peck

Pricing Strategy vs. Volume Growth and Use of Portfolio Leverage

Sentiment: Mixed

"On price, we have said we would return to our normal range, which is 2% to 3%, which is what you can assume in this guidance with the balance, of course, being volume." — Wetteny Joseph
"We do not see significant shifts in our approach to pricing…Our pricing has always been and remains an element that we take into consideration product by product, market by market, and the value…the products provide." — Wetteny Joseph

Bull Case

Bulls argue that Zoetis’ diversified portfolio, entrenched leadership in parasiticides and dermatology, and a deep late‑stage pipeline set up a temporary 2026 digestion year before growth re‑accelerates toward its historical high‑single‑digit trajectory in 2027 and beyond.

Bear Case

Bears contend that rising competition in key franchises, sustained OA pain headwinds, macro‑driven pressure on U.S. companion animal demand, and reduced reliance on price hikes signal a structurally slower, lower‑margin growth profile than investors have historically paid a premium for.

Looking Ahead

Investors will be closely watching Zoetis Inc.'s next quarterly report for continued execution, particularly around 2026 Top‑Line Guidance (3–5%) vs. Accounting Noise and Macro Headwinds. With operating margins at 34.6%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Zoetis Inc.'s revenue in Q4 2025?

Zoetis Inc. reported Q4 2025 revenue of $2.4B, representing a +3.0% year-over-year change.

Did Zoetis Inc. beat earnings expectations in Q4 2025?

The stock declined -2.4% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Bulls argue that Zoetis’ diversified portfolio, entrenched leadership in parasiticides and dermatology, and a deep late‑stage pipeline set up a temporary 2026 digestion year before growth re‑accelerates toward its historical high‑single‑digit trajectory in 2027 and beyond.

What is the bull case for ZTS stock?

The bull case for ZTS centers on: Bulls argue that Zoetis’ diversified portfolio, entrenched leadership in parasiticides and dermatology, and a deep late‑stage pipeline set up a temporary 2026 digestion year before growth re‑accelerates toward its historical high‑single‑digit trajectory in 2027 and beyond.

What is the bear case for ZTS stock?

The bear case for ZTS centers on: Bears contend that rising competition in key franchises, sustained OA pain headwinds, macro‑driven pressure on U.S. companion animal demand, and reduced reliance on price hikes signal a structurally slower, lower‑margin growth profile than investors have historically paid a premium for.

How has ZTS stock performed since its Q4 2025 earnings?

ZTS moved -2.4% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +2.6% since earnings. Year-to-date, the stock has returned -0.1%.

Browse all 400+ earnings reports →

Learn More

Analyze ZTS in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Zoetis Inc. and 400+ other stocks, explore the full platform.

Open ZTS on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.